Jakob Loven

Jakob Loven, Ph.D., joined Nextech Invest as Partner in 2017, bringing the passion of a serial entrepreneur. Jakob joined Nextech from Third Rock, where he focused on new company formation in the areas of oncology and emerging technologies. He also served on the firm’s scientific ideation team, overseeing several early-stage projects and leading efforts to transform emerging areas of science into innovative drug discovery companies with unique scientific platforms. While at Third Rock, Jakob launched Relay Therapeutics in Cambridge Massachusetts, which was selected as one of Fiercebiotech’s Fierce 15 in 2017. Prior to Relay, Jakob was a Founding Scientist of Syros Pharmaceuticals (NASDAQ: SYRS), which was founded on his co-discoveries in gene regulation sciences and technologies. Jakob holds a BA in Biomedical Sciences from the Anglia Ruskin University of Cambridge, earned his Ph.D. in Medical Sciences from Karolinska Institutet, and conducted his postdoctoral fellowship at the Whitehead Institute for Biomedical Research. During his appointment at the Whitehead Institute, Jakob pioneered the field of gene regulation research through numerous scientific findings, authoring several high-impact journal articles.

Jakob manages Nextech’s investments in Autolus, A2 Biotherapeutics, Arvinas and Turning Point Therapeutics.